A phase I/II study (NCT02420717) initiated at MD Anderson assessed the safety and efficacy profile of dasatinib with hyper-CVAD (cyclophosphamide, vincristine, doxorubicin, dexamethasone) in adolescents and young adults with relapsed or recurrent Ph-like ALL with ABL-class fusions. The gene discussed is ABL1; the disease is acute lymphoblastic leukemia.